146 related articles for article (PubMed ID: 30806569)
21. Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease.
Lubeck D; Agodoa I; Bhakta N; Danese M; Pappu K; Howard R; Gleeson M; Halperin M; Lanzkron S
JAMA Netw Open; 2019 Nov; 2(11):e1915374. PubMed ID: 31730182
[TBL] [Abstract][Full Text] [Related]
22. Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability.
Casado V; Martínez-Yélamos S; Martínez-Yélamos A; Carmona O; Alonso L; Romero L; Moral E; Gubieras L; Arbizu T
BMC Health Serv Res; 2006 Nov; 6():143. PubMed ID: 17078879
[TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.
Caloyeras JP; Zhang B; Wang C; Eriksson M; Fredrikson S; Beckmann K; Knappertz V; Pohl C; Hartung HP; Shah D; Miller JD; Sandbrink R; Lanius V; Gondek K; Russell MW
Clin Ther; 2012 May; 34(5):1132-44. PubMed ID: 22541587
[TBL] [Abstract][Full Text] [Related]
25. Corneal Collagen Cross-Linking in the Management of Keratoconus in Canada: A Cost-Effectiveness Analysis.
Leung VC; Pechlivanoglou P; Chew HF; Hatch W
Ophthalmology; 2017 Aug; 124(8):1108-1119. PubMed ID: 28457614
[TBL] [Abstract][Full Text] [Related]
26. Characterizing Heterogeneity Bias in Cohort-Based Models.
Elbasha EH; Chhatwal J
Pharmacoeconomics; 2015 Aug; 33(8):857-65. PubMed ID: 25851486
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
[TBL] [Abstract][Full Text] [Related]
28. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
Spencer M; Briggs AH; Grossman RF; Rance L
Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
[TBL] [Abstract][Full Text] [Related]
29. Costs and quality of life of multiple sclerosis in Sweden.
Berg J; Lindgren P; Fredrikson S; Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S75-85. PubMed ID: 17310342
[TBL] [Abstract][Full Text] [Related]
30. Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations?
Honkanen LA; Mushlin AI; Lachs M; Schackman BR
J Am Geriatr Soc; 2006 Nov; 54(11):1658-65. PubMed ID: 17087691
[TBL] [Abstract][Full Text] [Related]
31. The Health and Productivity Burden of Migraines in Australia.
Tu S; Liew D; Ademi Z; Owen AJ; Zomer E
Headache; 2020 Nov; 60(10):2291-2303. PubMed ID: 33026675
[TBL] [Abstract][Full Text] [Related]
32. [Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain].
Piñol C
Neurologia; 2016 May; 31(4):247-54. PubMed ID: 25976942
[TBL] [Abstract][Full Text] [Related]
33. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
34. Population norms for quality adjusted life years for the United States of America, China, the United Kingdom and Australia.
Palmer AJ; Campbell JA; de Graaff B; Devlin N; Ahmad H; Clarke PM; Chen M; Si L
Health Econ; 2021 Aug; 30(8):1950-1977. PubMed ID: 34018630
[TBL] [Abstract][Full Text] [Related]
35. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis.
Kobelt G; Jönsson L; Henriksson F; Fredrikson S; Jönsson B
Int J Technol Assess Health Care; 2000; 16(3):768-80. PubMed ID: 11028132
[TBL] [Abstract][Full Text] [Related]
36. The economic and health burden of stroke among younger adults in Australia from a societal perspective.
Tan E; Gao L; Collier JM; Ellery F; Dewey HM; Bernhardt J; ; Moodie M
BMC Public Health; 2022 Feb; 22(1):218. PubMed ID: 35114974
[TBL] [Abstract][Full Text] [Related]
37. Cost Burden and Cost-Effective Analysis of the Nationwide Implementation of the Quality in Acute Stroke Care Protocol in Australia.
Marquina C; Ademi Z; Zomer E; Ofori-Asenso R; Tate R; Liew D
J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105931. PubMed ID: 34157669
[TBL] [Abstract][Full Text] [Related]
38. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.
Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
Rheumatology (Oxford); 2005 Sep; 44(9):1169-75. PubMed ID: 15956093
[TBL] [Abstract][Full Text] [Related]
39. Costs and quality of life of multiple sclerosis in Italy.
Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
[TBL] [Abstract][Full Text] [Related]
40. Estimate of the cost of multiple sclerosis in Spain by literature review.
Fernández O; Calleja-Hernández MA; Meca-Lallana J; Oreja-Guevara C; Polanco A; Pérez-Alcántara F
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):321-333. PubMed ID: 28726515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
